- Home
- LRMR vs ENLV Comparison
LRMR vs ENLV Comparison
Compare LRMR & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRMR | ENLV |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.0M | 249.3M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LRMR | ENLV |
|---|---|---|
| Price | $5.16 | $1.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $16.29 | $13.00 |
| AVG Volume (30 Days) | ★ 6.3M | 293.0K |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.66 |
| 52 Week High | $6.42 | $2.10 |
Technical Indicators
Market Signals| Indicator | LRMR | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 63.82 | 54.93 |
| Support Level | $3.18 | $0.98 |
| Resistance Level | $5.37 | $1.23 |
| Average True Range (ATR) | 0.52 | 0.08 |
| MACD | 0.16 | -0.00 |
| Stochastic Oscillator | 66.13 | 60.00 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.